Vitaherpavac

Quick links

Choose a section

Quick links to important sections

Advertisements

Vitaherpavac

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Vitaherpavac

Vitaherpavac is an immunological preparation classified as a therapeutic antiviral vaccine intended for individuals already exposed to the Herpes Simplex Virus (HSV).


Quick Facts

Property Description
Active Ingredients Inactivated Herpes Simplex Virus Antigens (Type 1 and Type 2)
Form Lyophilizate (dry powder) for Solution for Injection
Pharmacological Class Immunological Preparation; Antiviral Vaccine
General Purpose Induction of specific immunity against HSV
Origin Derived biological product (inactivated viral culture)

What Type of Medicine is Vitaherpavac?

Vitaherpavac belongs to the pharmacological class of immunological preparations, specifically acting as a divaccine that targets two types of the virus. It is defined as a therapeutic vaccine, meaning it is administered to people who have already contracted the infection, rather than serving as a prophylactic measure against primary infection. This positioning is clinically recognized for its use in patients with chronic, frequently recurring herpes infections.

Composition and Physical Form

The active components are the purified specific antigens derived from the Herpes Simplex Virus Type 1 and Type 2. It is a combination product utilizing inactivated (killed) viral material, which ensures the vaccine is non-infectious. The preparation is supplied as a lyophilizate—a sterile, dry powder that requires dissolving prior to use, typically administered via the intradermal route. Research indicates that the use of inactivated HSV antigens is a method studied for inducing a durable, virus-specific T-cell response in humans.

What is the General Purpose of this Therapeutic Vaccine?

The general purpose of Vitaherpavac is the induction of specific immunity against HSV. By introducing the inactivated antigens, the product stimulates the body's defenses to generate targeted immune memory cells and anti-herpetic antibodies. This targeted immunological reinforcement is intended to enhance the host immune system's specific capacity for antiviral action, which supports the overall management of the condition.

Advertisements

What side effects are possible with Vitaherpavac?

Possible side effects and safety information

The safety profile for this immunological preparation is established by regulatory documents from government health authorities, classifying documented adverse reactions by frequency and physiological system.

Very Common reactions (ge 1/10) are generally local and transient, primarily involving the administration site. These include pain, redness (erythema), and swelling at the injection area. Common systemic reactions in this category include myalgia (muscle pain), fatigue, and headache.

Common reactions (ge 1/100 to < 1/10) include generalized symptoms such as fever and chills. Reactions are grouped into System-Organ Classes (SOCs), which officially document effects on the Nervous System (e.g., headache, dizziness), Musculoskeletal System, and Gastrointestinal System (e.g., nausea, vomiting).

Rare reactions (ge 1/10,000 to < 1/1,000) may involve the Immune System, including hypersensitivity reactions such as rash or urticaria. The label documents the risk of Serious Adverse Reactions, which include anaphylaxis and, very rarely, Guillain-Barré Syndrome (GBS), with an increased risk observed during the 42 days following administration.

Safety Restrictions and Limitations are defined in the label. Administration is contraindicated in individuals with a known severe allergy to any component of the vaccine. Use is typically postponed in patients with an acute moderate to severe febrile illness. For Pregnancy and Lactation, official documents advise use only when the potential benefit is clearly justified, due to limited data.

Advertisements

Overdose and Emergency Response

Suspected overdose with this immunological preparation is officially documented as primarily manifesting as an exaggeration of known adverse reactions. These manifestations may include intensified local injection site reactions, such as increased erythema (redness) and swelling. Systemic effects can also be exacerbated, presenting as more severe signs like higher pyrexia (fever) and pronounced headache.

Any Severe Systemic Reaction or the potential for anaphylaxis is explicitly documented as a critical event requiring immediate action. Regulators mandate that individuals must seek immediate medical attention upon suspicion of overdose, and contact emergency services if severe symptoms are present. These severe outcomes represent the primary threshold for mandated urgent help-seeking.

The official labeling confirms that no specific antidote is known for Vitaherpavac's active components. Consequently, overdose management is restricted to the provision of symptomatic and supportive treatment. Clinical management often necessitates hospital monitoring and continuous clinical observation of vital signs until stability is confirmed. No distinct population-specific considerations regarding overdose severity are formally documented in the general regulatory information.

Advertisements

Therapeutic Uses of Vitaherpavac

What Vitaherpavac Treats: Main Uses and Benefits

This class of preparation is commonly used for long-term management of recurrent disease. This approach is considered relevant for patients with chronic recurrent herpetic infection, addressing conditions that create noticeable physiological strain and involve episodic or fluctuating manifestations.

This preparation primarily assists in managing the high-frequency pattern of disease seen in recurrent herpes simplex virus infections, including manifestations in the mouth, lips (labial herpes), genitals, and the eyes (ophthalmic herpes).

“The core therapeutic goal is to support the patient during episodes of heightened discomfort by managing the recurrent disease pattern.”

Easing the Frequency of Outbreaks

The core therapeutic benefit is the influence on the recurrent pattern, and it is applied to help reduce the frequency of symptomatic relapses over time. By contributing to the extension of the relapse-free interval, it helps improve day-to-day comfort and assists with maintaining functional stability for patients with frequently relapsing disease. The use of this preparation is associated with the clinical context of remission.


Quick Fact: Relief for Recurrent Herpes
Primary Therapeutic Focus: Helping to reduce the frequency of recurrences.
Target Conditions: Chronic recurrent HSV infection (genital, labial, ophthalmic).
Patient Benefit: Contributes to improved comfort by contributing to the extension of remission periods.

Regulatory References

  1. National Library of Medicine on therapeutic HSV vaccines
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Vitaherpavac?

Vitaherpavac is an immunological preparation indicated only for individuals with Chronic Recurrent Herpetic Infection (CHGI) who are strictly in the remission stage. Eligibility is often defined by the frequency of recurrence, typically requiring three or more episodes per year. Older adults are considered eligible for use on general grounds, though the regulatory documentation does not explicitly establish a minimum age for pediatric use.

Absolute Contraindications

Use is strictly prohibited in patients with specific underlying health risks, representing absolute contraindications listed in the official instructions:

  • Presence of Malignant Neoplasms.
  • Active Symptomatology of AIDS.
  • Known Hypersensitivity to Gentamicin or other antibiotics of the aminoglycoside class.
  • Pregnancy and Breastfeeding are both documented as absolute contraindications.

Conditional Use and Restrictions

Administration is temporarily prohibited during periods of clinical instability or disease activity:

  • Active Infection: Vaccination must be postponed until the herpes infection is in remission, requiring a delay of up to 14 days after clinical signs disappear (up to 1 month for ophthalmic herpes).
  • Acute or Chronic Disease: Prohibited during any acute infectious or non-infectious disease or when chronic conditions are in a state of exacerbation or decompensation. Use is permitted only after full recovery and stabilization of the condition.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Vitaherpavac is strictly defined by the information provided in its official regulatory documentation, which specifies constraints related to co-administration with other medicinal products and substances. This information strictly adheres to the standards set by national health authorities for immunological preparations, reflecting a high-level review of potential drug-drug and drug-substance scenarios.

Officially Documented Interaction Status

The regulatory prescribing information explicitly addresses the formal status of product combinations, documenting the absence of specific known risks.

Category Official Regulatory Status
Contraindicated Combinations None documented.
Pharmacokinetic Interactions None documented.
Timing-Based Rules None documented with other medicinal products.
Food, Alcohol, Herbal Products None documented.

The official regulatory label for Vitaherpavac states that no cases of incompatibility with other medicinal products have been formally identified in the prescribing information. This includes the absence of documented pharmacodynamic interactions. Consequently, the documentation does not contain any required time separation rules for co-administration or list specific drug-drug interactions, nor are any population-specific interaction cautions noted. Furthermore, the label explicitly confirms the absence of contraindications based on interaction risk when co-administered with other medicines. As an immunological preparation, the product is not associated with typical metabolic interactions involving CYP enzymes or drug transport proteins, and no such mechanistic interactions are documented in its official label. This regulatory profile establishes that no substances are officially listed as altering the systemic exposure or clearance of the product.

Advertisements

Mechanism of Action

Vitaherpavac is a dry, inactivated culture vaccine containing Herpes Simplex Virus (HSV) Type 1 and Type 2 antigens. Upon intramuscular or intradermal administration, the viral antigens are presented to Antigen-Presenting Cells (APCs), primarily Dendritic Cells and Macrophages, at the injection site. The APCs internalize the inactivated viral components and process them into peptides, which are then presented on the cell surface via Major Histocompatibility Complex (MHC) molecules, specifically MHC Class I and MHC Class II

.

This presentation activates the adaptive immune system by stimulating the proliferation and differentiation of CD4+ Helper T-lymphocytes and CD8+ Cytotoxic T-lymphocytes that are specific to the HSV antigens. The activated CD4+ T-cells promote the maturation of B-lymphocytes into plasma cells, leading to the systemic production of anti-HSV antibodies (a humoral response). Concurrently, the activated CD8+ T-cells migrate into peripheral tissues and sensory ganglia, becoming available to recognize and lyse host cells expressing specific viral antigens (a cell-mediated cytotoxic response).

This immunological cascade establishes cellular resistance and immunological memory against the HSV structural proteins and antigens.

Advertisements

Dosage and Administration Information

The use of Vitaherpavac, a therapeutic vaccine containing inactivated Herpes Simplex Virus antigens, is governed by a precise schedule and specific administration requirements.

Administration Scope

Parameter Instruction
Route of administration Intradermal injection for the lyophilizate form.
Dosing schedule (Primary Course) The initial course consists of 5 doses (injections).
Preparation requirements The lyophilizate (dry powder) must be reconstituted (dissolved) with a specified solvent immediately before administration.
Age-group administration rules Standard adult dosing is used; specific dose adjustments for other populations are not commonly detailed in the general labeling.
Special procedural conditions Administration must occur only during the remission stage of the disease, not earlier than 10 days following the complete disappearance of all clinical manifestations of an outbreak.

Frequency and Procedural Schedule

Administration is classified as cyclic/interval use. The injections in the primary course are administered with an interval of 7 to 10 days between doses. The entire course must be conducted in a medical institution under the supervision of qualified medical staff.

If a recurrence or exacerbation occurs after any injection, the vaccination must be temporarily discontinued. The course may only be resumed after the new clinical episode resolves and the mandatory 10-day waiting period has elapsed. Following the completion of the five-dose primary course, a revaccination course is typically scheduled after a period of approximately 6 months.

Advertisements

Recent Clinical Evidence

Vitaherpavac: Recent Clinical Evidence


Evidence for Use in Chronic Recurrent Herpetic Infection

This section summarizes the structure of clinical trials that have studied the use of this therapeutic vaccine class in conditions characterized by fluctuating or episodic manifestations of herpes simplex virus (HSV). The research examined its use for conditions which included recurrent infections of the mouth, lips, genitals, and eyes. Researchers examined patient groups with a clinical diagnosis of chronic, frequently recurring herpes. Study designs included comparative clinical trials and non-randomized trials that monitored patient cohorts over a set period. The main outcomes measured included the frequency of symptomatic recurrences and the length of time between those outbreaks, known as the relapse-free interval.

Types of Studies and Outcomes Measured

The research was studied for the immune response in patients who are already infected. In addition to clinical measures, researchers monitored immunogenicity. This was evaluated in studies that measured the body’s response by quantifying specific immune responses in participants. The available evidence base consists of trials that primarily included adults who have a clinical history of recurrent disease, but the evidence is largely based on non-randomized or comparative clinical trials rather than the large-scale double-blind, placebo-controlled Randomized Controlled Trials (RCTs) often found in major global medical databases.

Long-Term Studies and Follow-up

Research has also examined the potential for sustained changes in the disease pattern over time. The follow-up durations reported in some studies are intermediate to long, with periods of observation sometimes extending up to multiple years. This long-term monitoring was observed in cohorts to assess how long-lasting any observed changes to the recurrence pattern may be. Long-term effects are not fully established by globally recognized high-certainty evidence.

What Is Still Uncertain About the Research for Vitaherpavac

Scientific review of the available research highlights several areas where certainty remains low and where more research is ongoing. A key limitation is the modest sample sizes and limited availability of large, double-blind, international RCTs. Evidence quality varies across studies, and there is a reliance on non-randomized clinical trials. The findings from different trials varied regarding the consistency of the measured changes. Furthermore, the existing evidence provides limited insight into factors that may influence individual patient response, meaning research provides context but not individual predictions. The overall research landscape was studied for the recurrent disease pattern and research was not conducted on preventing the initial HSV infection.

Key Studies & References

  1. World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) – Search Portal
  2. US National Library of Medicine (NIH) - PubMed Central
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Vitaherpavac (FAQ)

Q: How is Vitaherpavac different from standard antiviral pills?

A: According to official product information, Vitaherpavac is classified as an immunological preparation, which is a type of therapeutic vaccine. It functions by introducing inactivated viral antigens to the body to stimulate the specific immune system. This process is intended to help the body establish immunological memory against the Herpes Simplex Virus.


Q: Are there any known interactions between Vitaherpavac and common pain relievers?

A: Regulatory documentation explicitly states that no cases of incompatibility with other medicinal products have been formally identified in the prescribing information. This includes common pain relievers, meaning the official label does not document any risk of interaction.


Q: Does Vitaherpavac interact with birth control medication?

A: According to the official regulatory documentation, there are no cases of incompatibility documented with other medicinal products. The prescribing information does not list birth control medication as having a formal interaction risk with Vitaherpavac.


Q: How is the research evidence for Vitaherpavac summarized in official reviews?

A: Official reviews of the research indicate that studies examined the use of Vitaherpavac for chronic recurrent infections. The main outcomes assessed were changes in the frequency of symptomatic recurrences and the length of the relapse-free interval (the time between outbreaks). The evidence base consists of both comparative clinical trials and non-randomized trials.


Q: Can I stop using Vitaherpavac suddenly, or should I finish a full course?

A: Official administration guidelines detail a primary course of 5 injections that is administered on a defined schedule. The documentation provides a rule for temporary discontinuation if a herpes recurrence occurs, with the course resuming only after the episode resolves. The label does not address stopping the course for reasons other than disease recurrence.


Q: How long does the described effect of Vitaherpavac typically last after use?

A: The regulatory documentation defines the use of the product as cyclic. Following the completion of the initial course, a revaccination course is typically scheduled after a period of approximately 6 months.


Q: Are there different versions or strengths of Vitaherpavac available?

A: Official regulatory information describes the product only as a lyophilizate (a dry powder) for a solution for injection. This single presentation contains inactivated antigens for both Herpes Simplex Virus Type 1 and Type 2. There are no other distinct versions or strengths documented in the general labeling.


Q: Is Vitaherpavac available in different forms, such as pills or an injection?

A: Vitaherpavac is supplied in the physical form of a lyophilizate, which is a sterile dry powder. This powder is required to be dissolved prior to use and is administered via intradermal injection. Official documents do not list any other forms, such as pills or tablets.


Q: Are there any specific lifestyle factors mentioned in relation to Vitaherpavac use?

A: The official interaction profile addresses factors such as Food, Alcohol, and Herbal Products. For these lifestyle factors, the regulatory documentation states that no interactions or constraints have been formally documented.


Q: Is the efficacy of Vitaherpavac considered high across all patient groups?

A: The scientific review of the evidence indicates that findings varied regarding the consistency of measured changes among studies. Furthermore, the evidence provides limited insight into individual factors that may influence a patient's response to the product.


Q: Why do official descriptions avoid making strong claims about Vitaherpavac outcomes?

A: Scientific review suggests that a key factor is the reliance on studies with modest sample sizes and the limited availability of large-scale, double-blind, placebo-controlled trials often used for high-certainty evidence. This contributes to a general assessment of low certainty for some of the findings, which informs the language used in official product descriptions.


Q: What are the general expectations for someone starting Vitaherpavac?

A: Research has examined the product's use by monitoring its effect on the pattern of recurrent disease. The main outcomes studied included changes in the frequency of symptomatic recurrences and the length of the relapse-free interval, which is the time between outbreaks.


Q: What kind of studies support the use of Vitaherpavac?

A: The evidence base that supports the use of Vitaherpavac consists of clinical trials that primarily included comparative clinical trials and non-randomized trials. These studies focused on monitoring patient cohorts with recurrent herpes over a set period.


Q: Is it normal to feel a mild reaction at the application site of Vitaherpavac?

A: Official documentation notes that reactions at the administration site, such as pain, redness (erythema), and swelling, are listed as Very Common. These local reactions occur in a high number of patients and are generally described as transient (short-lasting).


Q: Can Vitaherpavac be used by children, according to official information?

A: According to the official documentation, the product is indicated for adults, and the labeling does not explicitly establish a minimum age for pediatric use. Furthermore, specific dose adjustments for populations outside the standard adult dosing are not commonly detailed in the general instructions.


Q: Does Vitaherpavac interact with common supplements like Vitamin C or Zinc?

A: The official regulatory interaction profile addresses substances such as Food, Alcohol, and Herbal Products and states that no interactions or constraints are documented for these factors. The documentation does not specify any known interactions with common vitamin or mineral supplements.


Q: Can people with liver or kidney issues generally use Vitaherpavac?

A: The official label conditionally prohibits use when any chronic condition is in a state of exacerbation or decompensation. However, the documentation does not list specific contraindications or dose adjustments related to stable hepatic (liver) or renal (kidney) impairment.


Q: What is the scientific basis described for how Vitaherpavac works?

A: The scientific basis for Vitaherpavac is the introduction of inactivated viral antigens to the immune system. This process is intended to activate specific T-lymphocytes (a type of immune cell) and stimulate the production of anti-HSV antibodies. The overall goal is to establish immunological memory against the virus.

Advertisements

How should Vitaherpavac be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines for vaccines, including lyophilized preparations like Vitaherpavac, establish strict conditions to maintain potency and safety.

Storage & Disposal Scope Official Regulatory Requirements
Storage Temperature The product must be stored refrigerated, maintained strictly between 2 C and 8 C (36 F and 46 F).
Handling Prohibition Do Not Freeze. Freezing causes irreversible loss of potency, and any product exposed to freezing temperatures must be discarded.
Protection Requirements Vials must be protected from light by remaining in the original carton until the time of use.
Stability After Preparation Once the vaccine is reconstituted or prepared, it must be administered immediately or within the specific Beyond-Use Time stated on the label (typically a short, defined window).
Disposal Instructions Unused, expired, or compromised vaccine and all used syringes/vials must be managed as pharmaceutical or medical waste, following federal, state, and local disposal protocols, and must not be placed in household trash or flushed.

These constraints ensure the product remains stable and effective up to its printed expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vitaherpavac found in:

A-Z Index: